List view / Grid view
30 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim Animal Health reinforces its commitment to support applied research for the improved control of PRRS (Porcine Reproductive and Respiratory Syndrome) in Europe...
30 April 2014 | By Biogen Idec
Additional real-world data show tolerability profile consistent with pivotal studies...
30 April 2014 | By Waters
Powerful alternative to LIMS offers seamless lab-to-business connection for science-driven organizations...
29 April 2014 | By BioMarin
The first and only drug designed to address Morquio A syndrome is now available in Europe and the UK for children and adults with this rare genetic condition...
29 April 2014 | By Gilead
Gilead Sciences, Inc. announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi® (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus...
29 April 2014 | By Biogen Idec
Biogen Idec announced two-year data from its Phase 3 ADVANCE clinical trial for PLEGRIDY™ (peginterferon beta-1a) in people with relapsing forms of multiple sclerosis...
29 April 2014 | By The European Medicines Agency
In 2013, EudraVigilance received more than one million post-marketing expedited adverse-drug-reaction reports...
29 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the European Commission has granted marketing authorisation for Incruse® (umeclidinium)...
28 April 2014 | By Roche
First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy...
28 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced results from the Phase III SYNERGY trial...
28 April 2014 | By GlaxoSmithKline
GlaxoSmithKline and Medicines for Malaria Venture announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine...
28 April 2014 | By Pfizer
This is an announcement of a possible offer falling under Rule 2.4 of the City Code on Takeovers and Mergers (the “Code”)...
25 April 2014 | By Roche
Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older...
25 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the discontinuation of the phase 3 clinical trial conducted in Japan for nimotuzumab (DE-766) in Lung Cancer...
25 April 2014 | By Daiichi Sankyo
Kitasato Daiichi Sankyo Vaccine engaged in preparations to build a scheme to supply vaccines by the end of March 2014...
